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Abstract
Background: Electroporation is an established technique for enhancing plasmid delivery to many
tissues in vivo, including the skin. We have previously demonstrated efficient delivery of plasmid
DNA to the skin utilizing a custom-built four-plate electrode. The experiments described here
further evaluate cutaneous plasmid delivery using in vivo electroporation. Plasmid expression levels
are compared to those after liposome mediated delivery.
Methods:  Enhanced electrically-mediated delivery, and less extensively, liposome complexed
delivery, of a plasmid encoding the reporter luciferase was tested in rodent skin. Expression
kinetics and tissue damage were explored as well as testing in a second rodent model.
Results: Experiments confirm that electroporation alone is more effective in enhancing reporter
gene expression than plasmid injection alone, plasmid conjugation with liposomes followed by
injection, or than the combination of liposomes and electroporation. However, with two time
courses of multiple electrically-mediated plasmid deliveries, neither the levels nor duration of
transgene expression are significantly increased. Tissue damage may increase following a second
treatment, no further damage is observed after a third treatment. When electroporation
conditions utilized in a mouse model are tested in thicker rat skin, only higher field strengths or
longer pulses were as effective in plasmid delivery.
Conclusion: Electroporation enhances reporter plasmid delivery to the skin to a greater extent
than the liposome conjugation method tested. Multiple deliveries do not necessarily result in higher
or longer term expression. In addition, some impact on tissue integrity with respect to surface
damage is observed. Pulsing conditions should be optimized for the model and for the expression
profile desired.
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Background
The skin is an attractive target for gene therapy protocols for
cutaneous diseases, vaccines and several metabolic disor-
ders because it is easily accessible for both delivery and
monitoring. To fully take advantage of skin as a target for
gene transfer, it is important to establish an efficient and
reproducible delivery system. Electroporation as a tool for
the delivery of plasmid DNA is a strong candidate to meet
these delivery criteria. Electroporation-mediated cutaneous
plasmid DNA delivery has been demonstrated by many
groups [1,2] for the eventual purpose of gene therapy.
Liposome or vesicle-complexed plasmid DNA has also
been tested for enhancing transgene expression in the
skin. Topical delivery has been performed in intact skin
[3-9] and skin stripped of keratinocytes [10-12]. Intrader-
mal injection of liposomes has been performed in a rat
skin flap model [13]. This delivery may induce an
immune response and has therefore been tested in vaccine
delivery [8-11] and delivery has also been performed for
therapeutic purposes [3,10,13]. In the study presented
here, reporter expression was observed after intradermal
injection of liposome-complexed DNA alone and in com-
bination with in vivo electroporation.
Electroporation (EP) is a physical method that enhances
delivery of molecules to tissues in vivo. Confined electrical
pulses are delivered to tissues at levels which increase cell
permeability without killing the cells, enabling molecules
to pass through the cell membrane. EP has been used to
effectively deliver chemotherapeutic agents to tumors in
animals and in humans [14] and plasmid DNA to a vari-
ety of tissues in both animals and humans [1].
Recent studies have shown that electroporation efficiently
delivers plasmid DNA to the skin resulting in increased
local and serum expression levels compared to injection
alone [15-31]. Skin electroporation delivery has been suc-
cessfully performed in rodent [15,16,18-22,24,26-32],
rabbit [25], pig [16,17,23,32] and non-human primate
[16,32] model systems.
Several studies have been designed to use electrically
mediated plasmid delivery for vaccine purposes, includ-
ing hepatitis B surface antigen [17,22,23,25] and HIV
[32]. Electrically mediated plasmid delivery to the skin
has also been tested therapeutically. Delivery of the gene
encoding erythropoietin to the skin achieved significantly
elevated serum levels as well as significantly elevated
hematocrit compared to injection of plasmid without EP
[18]. Delivery of a plasmid encoding a growth factor
[24,28] or a transcription factor which controls growth
factor expression [31] increased wound healing. These
studies demonstrate the feasibility of using this approach
therapeutically or for increasing serum levels of a specific
protein.
Molecule delivery is more efficient when the field is
applied in more than one direction [33-35]. With two
plate electrodes, the electrode must be repositioned for
the second set of pulses. Therefore, a non-invasive four-
plate electrode (4PE) was developed to allow the applica-
tion of two sets of pulses rotated 90° with respect to each
other, which makes pulse application more straightfor-
ward [29]. Delivery with this electrode results in reporter
gene expression equivalent or superior to commercially
available electrodes for delivery to the skin. The purpose
of the experiments described here is to further investigate
localized cutaneous plasmid delivery with the 4PE. Local-
ized transgene expression levels and kinetics and histolog-
ical damage were compared after the electrically mediated
delivery of plasmid DNA. Delivery with the electrode was
also tested in a larger rodent model, the rat.
Methods
Animals
Six to 7 week old female BALB/c mice (NCI) or 200–250
gram male Sprague Dawley rats were anesthetized in an
induction chamber charged with 3% isoflurane in O2 then
fitted with a standard rodent mask and kept under general
anesthesia during treatment.
Plasmid delivery
gWizLuc was commercially prepared (Aldevron, Fargo,
ND). Endotoxin levels were < 0.1 EU/μg plasmid. For in
vivo electroporation, 50 μl gWizLuc suspended to 2 μg/μl
in sterile injectable saline was injected intradermally.
Using a 4PE electrode [29], eight 100 V/cm 150 ms pulses
at a frequency of 1 Hz were immediately applied with a
BTX 830 pulse generator (BTX Molecular Delivery Sys-
tems, Holliston, MA) unless otherwise noted. For lipo-
some delivery, 100 μg gWizLuc was complexed with a
commercial preparation of DOTAP (N-[1-(2,3-dioleoy-
loxy) propyl]-N,N,N-trimethyl-ammonium-methyl-sul-
fate, (Roche Diagnostics, Mannheim, Germany) in a ratio
of 1:1.6 (w/w) [10] and 50 μl was injected intradermally.
Luciferase reporter assay
At the indicated time points after plasmid delivery, luci-
ferase activity was quantified as previously described [36].
The treated area was consistently 6 mm in diameter. How-
ever, since there was some variation in the diametric tissue
excised, activity was expressed in total ng luciferase per
treatment area. Values represent mean and standard error.
Experiments containing only two groups were analyzed
by Student's unpaired T test. Experiments with greater
than two groups were analyzed by nonparametric
ANOVA.Genetic Vaccines and Therapy 2008, 6:16 http://www.gvt-journal.com/content/6/1/16
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Histological analysis
For histological analysis, 50 μl 2 μg/μl gWizLuc was deliv-
ered using eight 150 ms 100 V/cm pulses with the 4PE. At
the time points indicated, the mice were euthanized and a
seven mm diameter circle of skin 2–3 mm thick that
encompassed the 6 mm diameter treatment area was
removed. After fixation in 10% neutral buffered formalin
for six hours, each sample was dehydrated in ascending
grades of ethanol, cleared in xylene, and infiltrated with
paraffin. Following embedding, tissues were cut into four
4 mm sections. Sections were stained with hematoxylin
and eosin and then examined histologically for damage.
Samples were graded using a schema including surface
damage, inflammation, bullae, muscle degeneration and
subepidermal necrosis in eight 4 × 7 mm sections [29].
For surface damage, the percentage of each section dam-
aged was determined. For the other damage assessments,
any damage seen within a low power field (40×), even
focal points, was considered positive. The percentage
reported was the number of positive fields seen (eight
fields per section and four sections per sample). The total
amount of damage was determined for each sample and
expressed as the mean and SEM of the percentage of the
total treatment area. Significance was determined for the
three groups by nonparametric ANOVA.
Results and discussion
EP delivery previously optimized in mouse skin was
directly compared to liposome-based delivery (Figure 1).
At 48 hours, the DNA:DOTAP formulation tested tended
to increase reporter expression. EP increased expression
significantly, nearly 20 fold higher than the liposome for-
mulation. When EP and liposome delivery were com-
bined, expression was not significantly higher than
injection alone. The combination of liposome delivery
and in vivo electroporation for plasmid delivery has been
compared in previous studies. Wells, et al. found no differ-
ence in transgene expression after delivery of a luciferase
encoding plasmid by electroporation with six 1 ms 800–
1600 V/cm pulses, with small unilamellar DOTAP lipo-
plexes, or with the combination to MC2 mouse mammary
tumors [37]. Cemazar, et al. found that transfection effi-
ciency of a plasmid encoding green fluorescent protein
was more effective in complex with lipofectin than naked
plasmid DNA injection when delivered to several mouse
tumor types. However, electrically mediated delivery of
plasmid alone using eight 5 ms 600 V/cm pulses signifi-
cantly increased transfection. The combination of com-
plexed DNA and electroporation was not significantly
different from electroporation alone [38].
There are several possible reasons as to why the results of
these three studies differ considerably. There are varia-
tions the lipid composition, the reporter gene delivered,
the in vivo electroporation parameters, and the method of
analysis (overall transgene expression vs. transfection effi-
ciency). In addition, these studies used a tumor, rather
than skin, model. Tumor cells typically divide more rap-
idly than skin cells. It is understood that both EP and lipo-
somes can destabilize cell membranes and, in this
particular case, perhaps the combination of the two is dis-
ruptive, leading to decreased cell survival and ultimately
decreased expression. Alternatively, exposure of the lipo-
somes to EP may release the DNA prior to contact with the
membranes and reduce the transport of plasmid through
the cell membrane which would also lead to reduced
transgene expression.
Clearly, EP enhances skin expression after intradermal
injection of plasmid DNA [15-23,25,26,29]. After a single
cutaneous delivery, significantly increased reporter
expression has been demonstrated in rabbits for two days
[25], in mice [27] and rats [18,19,26] to seven days, and
in mice to approximately two weeks [22,29]. The differ-
ences in levels and duration of expression may be due to
the different models, plasmid constructs, electrodes, elec-
troporation protocols, and methods of analysis used.
In an attempt to increase the duration of transgene expres-
sion, multiple deliveries were performed. Two delivery
time courses were tested, day 0 followed by days 2 and 4
Comparison of liposome and EP delivery of plasmid DNA Figure 1
Comparison of liposome and EP delivery of plasmid 
DNA. Luciferase expression in mouse skin 48 hours after 
delivery of 100 μg gWizLuc as described in materials and 
methods. Inj, injection only, n = 12; Lip, liposomes, n = 12; 
Electroporation, EP, n = 12; Lip+EP, liposomes + EP, n = 4. 
***p < 0.001 with respect to injection only; *p < 0.05 with 
respect to liposomes.Genetic Vaccines and Therapy 2008, 6:16 http://www.gvt-journal.com/content/6/1/16
Page 4 of 7
(page number not for citation purposes)
(Figure 2), and day 0 followed by days 10 and 20 (Figure
3). With deliveries at days 0, 2, and 4 (Figure 2), expres-
sion spiked 48 hours after the first delivery at 5.4 ± 1.4
total ng luciferase, similar to the levels observed previ-
ously [29]. This expression significantly decreased on days
4 and 6. Expression significantly peaked again at day 11 at
6.6 ± 1.9 total ng luciferase. This is possibly related to
when the skin tissue recovered from any damage pro-
duced by the EP process. Multiple deliveries did not signif-
icantly increase the duration of transgene expression. This
agrees with Lin, et al., who observed that two deliveries 24
hours apart did not result in increased luciferase expres-
sion [28] in a rat model.
When deliveries were performed on days 0, 10, 20, a sim-
ilar immediate increase in reporter expression to 5.7 ± 1.9
total ng luciferase was observed (Figure 3). Interestingly,
no spike in expression was observed after the day 10 deliv-
ery. However, day 12 expression was significantly higher
than injection alone. A small but insignificant spike in
expression was observed 48 hours after the day 20 deliv-
ery, and a statistically significant difference was also
observed at day 37. Similar to the first time course, these
multiple deliveries did not significantly alter the time
course of reporter expression from that of a single plasmid
delivery [29].
In this study, only a small increase in expression duration
is observed with either multiple treatment protocol. Skin
cell turnover time for mice is approximately 7–12 days. If
tissue trauma due to EP were limiting expression, cell
turnover should allow subsequent peaks in expression.
Cell turnover may not facilitate increased expression with
the short interval delivery, but with the second delivery
time course, one would expect long-term increased
expression especially following delivery at 20 days. For
these reasons, histological analysis of the delivery site was
performed (Table 1, Table 2). For both of these experi-
ments, the second and third deliveries were performed at
the same specific site as the initial delivery, since repeat
procedures at the same site might negatively impact cellu-
lar integrity and reduce expression.
After deliveries on days 0, 2, and 4, EP significantly
increased surface damage, bullae, and subdermal necrosis
over plasmid injection alone at both 4 and 6 days (Table
1). This damage may be ameliorated by the presence of
plasmid DNA. No delivery type significantly increased
inflammation more than any other. At day 4, muscle
degeneration was increased significantly over plasmid
injection alone, but this degeneration was resolved by day
6.
Duration and levels of skin luciferase expression after deliv- ery of plasmid by EP on days 0, 2, and 4 Figure 2
Duration and levels of skin luciferase expression after 
delivery of plasmid by EP on days 0, 2, and 4. Luci-
ferase expression in mouse skin after delivery of 100 μg 
gWizLuc at days 0, 2, 4, 6, 11, 18, and 26 as described in 
materials and methods. n = 12. *p < 0.05 with respect to 
injection only at the specified time point.
Duration and levels of skin luciferase expression after deliv- ery of plasmid by EP on days 0, 10, and 20 Figure 3
Duration and levels of skin luciferase expression after 
delivery of plasmid by EP on days 0, 10, and 20. Luci-
ferase expression in mouse skin after delivery of 100 μg 
gWizLuc at days 0, 2, 10, 12, 17, 20, 22, 30, 37, and 42 as 
described in materials and methods. n = 12. *p < 0.05 with 
respect to injection only at the specified time point.Genetic Vaccines and Therapy 2008, 6:16 http://www.gvt-journal.com/content/6/1/16
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In the longer time course, deliveries were performed at
days 0, 10, and 20, while histological analysis was per-
formed at days 12 and 22 (Table 2). In this time course,
low levels of surface damage were observed, although a
significant increase with EP alone was observed over plas-
mid injection alone at day 22. Inflammation was also
increased with EP alone at this time point. No significant
differences were observed between delivery types in bul-
lae, muscle degeneration, or subepidermal necrosis.
Although damage is observed in each time course follow-
ing the second delivery, this damage does not increase
after the third delivery. While there were no obvious safety
issues with repeat deliveries, the results presented here
suggest that repeat administrations should not be per-
formed at the same specific site.
It was important to demonstrate that plasmid delivery
with the 4PE would increase skin transgene expression in
a larger model with thicker skin, the rat. Pulses of 100 V/
cm and 150 ms resulted in the highest expression levels in
the mouse [29]. In mouse skin, 20 ms pulses of 100 or
200 V/cm pulses increased expression to approximately
60% of 100 V/cm 150 ms. However, in the study
described here, while several pulse types resulted in signif-
icantly higher reporter expression (Figure 4), a longer or
higher field strength pulse was necessary for the higher
levels of expression rat skin. This may reflect the differ-
ences in skin architecture between the two models. While
many EP protocols may increase transgene expression in
multiple models, some protocol optimization is necessary
based on skin structure and thickness.
Conclusion
Electroporation is an effective method for in vivo delivery
of plasmid DNA [1,2], and this approach is also an effec-
tive tool for cutaneous applications. As has been seen with
other tissues, a variety of EP protocols ranging from short,
high field strength to long, low field strength pulses as
well as both invasive and surface electrodes have been
tested. When developing a protocol for a skin based appli-
cation, it is important to consider all of these variables as
Table 1: Tissue damage after three deliveries on days 0, 2, and 4. 
DNA+EP- DNA-EP+ DNA+EP+
Surface Damage
Day 4 1.3 ± 0.5 14.2 ± 4.4** 9.5 ± 3.5
Day 6 2.4 ± 1.9 11.0 ± 3.0** 10.7 ± 3.0*
Inflammation
Day 4 68.1 ± 12.7 100 ± 0 75.0 ± 11.5
Day 6 66.7 ± 11.2 95.8 ± 4.2 59.7 ± 10.3
Bullae
Day 4 4.2 ± 4.2 47.2 ± 11.2* 43.1 ± 13.7
Day 6 4.2 ± 4.2 37.5 ± 6.5* 52.7 ± 13.1**
Muscle Degeneration
Day 4 59.7 ± 12.0 97.9 ± 2.1* 72.2 ± 11.3
Day 6 66.7 ± 9.4 95.8 ± 4.2 52.8 ± 11.6
Subepidermal Necrosis
Day 4 8.3 ± 5.6 48.6 ± 10.7* 43.8 ± 13.8
Day 6 12.5 ± 9.0 50.0 ± 10.7* 40.3 ± 13.5
Values represent the mean and SEM for three independent 
experiments (n = 4) for a total of 12 samples.
DNA, gWizLuc
EP, electroporation
**p < 0.01
*p < 0.05
Table 2: Tissue damage after three deliveries on days 0, 10, and 
20. 
DNA+EP- DNA-EP+ DNA+EP+
Surface Damage
Day 12 2.4 ± 0.9 0.5 ± 0.2 3.0 ± 1.2
Day 22 3.8 ± 1.1 0.3 ± 0.2* 3.0 ± 1.1
Inflammation
Day 12 68.0 ± 12.7 68.0 ± 9.3 95.8 ± 4.2
Day 22 52.6 ± 11.8 95.8 ± 4.2** 77.8 ± 6.9
Bullae
Day 12 31.9 ± 14.1 8.3 ± 5.6 29.2 ± 13.2
Day 22 12.7 ± 5.9 4.2 ± 4.2 23.6 ± 9.5
Muscle Degeneration
Day 12 68.0 ± 12.7 48.6 ± 10.7 84.7 ± 9.0
Day 22 55.1 ± 11.2 66.7 ± 11.2 79.2 ± 7.7
Subepidermal Necrosis
Day 12 23.6 ± 12.88 12.5 ± 8.5 38.9 ± 14.1
Day 22 25.9 ± 8.8 4.2 ± 4.2 16.7 ± 9.4
Values represent the mean and SEM for three independent 
experiments (n = 4) for a total of 12 samples.
DNA, gWizLuc
EP, electroporation
**p < 0.01
*p < 0.05Genetic Vaccines and Therapy 2008, 6:16 http://www.gvt-journal.com/content/6/1/16
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each will contribute to the levels and duration of expres-
sion obtained. Expression levels in response to delivery of
plasmids encoding potentially toxic molecules such as
cytokines should be tightly controlled with only short
term expression. Expression after delivery of plasmids
encoding potential vaccine candidates also may only
require short-term expression. However, in the case of
replacement of a defective protein such as Factor IX, long-
term expression is desirable.
The results obtained in the current study demonstrated
that a non-invasive surface electrode can be used to
deliver plasmid DNA to the skin. Delivery was successful
in both mice and rats. The highest expression levels in
each species were obtained with different EP parameters.
While this delivery method is safe, if an application is
being developed that requires multiple administrations, it
is advisable to not perform the repeat at the same exact
site as the first administration. As has been seen with
delivery to other tissues, EP is a safe and reliable method
to obtain efficient and effective delivery of plasmid DNA.
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